ABSTRACT. Objective. To establish the prevalence of endocrinologic disorders in children with neurofibromatosis type 1 (NF1) and the relationship between these disorders and cerebral abnormalities on magnetic resonance imaging.
ABBREVIATIONS. NF1, neurofibromatosis type 1; NIH, National Institutes of Health; CPP, central precocious puberty; GHD, growth hormone deficiency; VEP, visual evoked potentials; CT, computed tomography; MRI, magnetic resonance imaging; SD, standard deviation; GH, growth hormone; LHRH, luteinizing hormone-releasing hormone. N eurofibromatosis type 1 (NF1) is an autosomal-dominant disorder affecting 1 in 3300 individuals. Characteristic features are café-au-lait-colored spots, freckling in intertriginous regions, neurofibromas, and Lisch nodules (iris hamartomas). Diagnostic criteria have been established by National Institutes of Health (NIH). 1 Endocrine disorders have been reported in ϳ1% to 3% of all NF1 patients. In adults, pheochromocytoma is the most common disorder, presenting in ϳ1% of NF1 patients. 2 In children with NF1, central precocious puberty (CPP) is the most frequent endocrinopathy and is seen in 3% of NF1 patients compared with .06% in the general pediatric population. [2] [3] [4] Although various case reports have been published, the prevalence of growth hormone deficiency (GHD) in children with NF1 is unknown and is assessed in this paper.
Listernick et al 5 reported that routine magnetic resonance neuroimaging in 176 children with NF1 revealed optic pathway gliomas in 33 (19%). Almost half of these gliomas were asymptomatic. In particular, gliomas of the optic chiasm have been reported to cause endocrinologic disorders, especially CPP. 6 In a prospective follow-up study in a multidisciplinary NF1 clinic, we analyzed the prevalence of endocrinologic disorders in children and the relationship between these disorders and cerebral abnormalities on neuroimaging.
PATIENTS AND METHODS
Since 1985, a multidisciplinary NF1 team at Sophia Children's University Hospital in Rotterdam (including a pediatrician, dermatologist, pediatric neurologist, ophthalmologist, and clinical geneticist) has evaluated children suspected of having NF1 according to NIH criteria. Besides periodic clinical evaluations, xrays of the cranium and the entire spine and a visual evoked potential (VEP) are performed at presentation. Computed tomography (CT) scanning and/or magnetic resonance imaging (MRI) is initiated when indicated.
Before January 1995, 171 new cases were seen. NF1 was diagnosed in 122 children (58 girls, 64 boys). The average follow-up period in the NF1-affected group was 4.4 years (standard deviation [SD] ϭ 4.1). The mean age of these children at last examination date was 9.9 years (SD ϭ 5.3). Still at risk for CPP were 16 of 58 (28%) girls who were Ͻ8 years of age and 25 of 64 (39%) boys who were Ͻ9 years of age at last examination date. Of the remaining 49 children, 17 remained suspect for NF1, having only one diagnostic criterion, other than a positive family history. In 32 children, the diagnosis of NF1 was rejected.
CPP was defined as the appearance of secondary sexual characteristics before the age of 8 years in girls and 9 years in boys. Secondary sexual characteristics included breast development of at least Tanner stage B2 in girls and genital development of at least Tanner stage G2 and a testicular volume of Ն4 mL in boys. 7 In addition, increased growth velocity, accelerated bone maturation, and pubertal responses of plasma luteinizing hormone (Ͼ10 mU/L) during a standard luteinizing hormone-releasing hormone (LHRH) stimulation test were present in all cases. 8, 9 Pituitary gonadotropin response to LHRH was obtained after intravenous injection of 100 g of LHRH. Subsequently, serum samples were taken at 0, 30, and 60 minutes after injection. 10 The diagnosis of GHD was based on a decreased height velocity over a period of at least 6 months or a decrease in height SD score of Ͼ0.25/year. 11 In addition, maximum plasma growth hormone (GH) peaks remained below 20 mU/L in at least two standard pharmacologic provocation tests (clonidine, arginine). After administration of 0.15 mg/m 2 clonidine orally or 0.5 g/kg body weight of arginine solution intravenously in 30 minutes, GH plasma values were measured at 0, 30, 60, 90, 120, and 150 minutes for the clonidine test, and at 0, 15, 30, 75, 90, and 120 minutes for the arginine test. Plasma GH was determined by a specific radioimmunoassay, using polyclonal antibodies after acid chromatography. 12 Prepubertal girls were estrogen-primed from the age of 8 years and prepubertal boys from the age of 9 years. A plasma insulin-like growth factor 1 value of 2 SDs below the reference values for age supported a diagnosis of GHD. 12 Other causes of decreased growth velocity were excluded.
Thyroid hormones were evaluated in all patients suspected of having an endocrinologic abnormality; no abnormalities were detected. Bone ages were analyzed according to Greulich and Pyle. 12a When bone age and chronologic age differed by Ͼ1 year, bone age was considered divergent.
In our population, CT and MRI of the brain were performed only on indication. Indications included endocrinologic disorders; ophthalmologic abnormalities such as optic atrophy, a relative afferent pupillary defect, an abnormal Ishihara color vision test, or an abnormal VEP; mental retardation; and various other neurologic abnormalities. In all patients suspected of having an optic pathway glioma, a special protocol for the detection of these gliomas was used. 13 All patients with an endocrinologic disorder were evaluated by MRI.
CPP patients were treated with the LHRH analogue Triptoreline (Ferring, Hoofddorp, the Netherlands), a depot preparation, once every 4 weeks intramuscularly. In GHD patients, treatment was initiated with recombinant human GH.
Children who developed endocrinologic abnormalities secondary to cranial irradiation for a progressive optic pathway glioma or malignancy were excluded from this study.
The study protocol was approved by the medical ethics committee of the Medical Faculty and the University Hospital Sophia/ Dijkzigt.
Data were analyzed using Dbase IV (Ashton-Tate, Amsterdam, the Netherlands) and SPSS (Statistical Products and Services Inc, Chicago, IL).
RESULTS
Endocrinologic disorders were diagnosed in 6 of the 122 children (5.0%; 95% CI: 0.3%-9.7%), children with definite NF1. All patients were boys. CPP was diagnosed in 3 (2.5%) of the 122 children (Table 1) . Mean age at diagnosis was 7.3 years. GHD was detected in 3 (2.5%) of the 122 children ( Table 1) . The mean age at diagnosis was 9 years. In 5 of the 6 children, NF1 was also diagnosed in one of the parents (3 mothers, 2 fathers) .
In children diagnosed with CPP, a chiasma glioma was seen on MRI in one child (patient A). Patients B and C showed no optic pathway glioma on MRI and had normal VEP, ophthalmologic, and neurologic examinations (Table 1) . Furthermore, a chiasma glioma was observed in one child (patient D) diagnosed with GHD (Table 1) .
Although no routine neuroimaging studies were performed, optic pathway gliomas were reported in 15 of 122 children with NF1 (12.3%; 95% CI: 6.5%-18.1%); 6 of the 15 (40%) were located in the optic nerve and in 9 of the 15 (60%), the optic chiasm was involved. In 5 of the 15 (33.3%) children with an optic pathway glioma, no ophthalmologic abnormalities were observed after visual examinations and funduscopy; in 14 of the 15 (93.3%) VEPs were abnormal. Endocrinologic disorders developed in 2 of the 9 children (22.2%; 95% CI: 10.2%-34.2%) with an optic chiasm glioma; no endocrine disorders were seen in children with an optic nerve glioma.
In total, 3 of 15 children (20%) were treated with radiotherapy for a progressive optic pathway glioma (mean age, 9.7 years); 2 of the 3 (66.6%) went on to develop GHD (patients G and H), although patient H developed this complication after the follow-up period. In 1 other child (patient I), both GHD and CPP developed after radiotherapy of the cranium for an astrocytoma. These 3 children were not included in this study.
DISCUSSION
The prevalence of GHD in children with NF1 was 2.5%, significantly higher than the 0.03% observed in the general pediatric population.
14 In 1 of the 3 children with GHD, a chiasma glioma was detected; 1 of the 9 (11.1%) children with a chiasma glioma presented with GHD. In our 3 cases, no growth of neurofibromas that could be ascribed to GH therapy was observed during clinical follow-up.
In our study, the prevalence of CPP is similar to the 3% observed by Habiby et al 6 ( Table 2 ). In contrast, we did not find evidence that optic chiasm glioma is a prerequisite for CPP, because only one of three children with CPP had an optic chiasm glioma at the time of diagnosis. This is the first observation demonstrating that a chiasma glioma can be absent in the presence of CPP, using MRI.
Strikingly, in our study, all endocrinologic disorders were observed in boys. In the literature, CPP is reported 8 times more often in girls than in boys and is sporadic and idiopathic in most cases. 15 However, underlying organic disorders are more commonly discovered in male patients. Habiby et al 6 found a female:male ratio of 2:5 in children with NF1 and CPP, as opposed to a female:male ratio of 22:11 in children with an optic pathway glioma. 4 It appears that being a male with NF1 somehow predisposes one to CPP without an apparent explanation.
Saxena 16 was the first to report precocious puberty as well as marked growth retardation in children with NF1. Various case reports published later on endocrine manifestations in NF1 [17] [18] [19] [20] concerned primarily CPP (Table 2) , not GHD. Comparison of the studies is difficult because of the lack of clinical data as well as the fact that diagnostic criteria for NF1 were only defined by NIH in 1987. In addition, detection of optic pathway glioma with neuroimaging became more sensitive with the introduction of MRI. Generally, it was thought that all endocrinologic disorders in NF1 could be attributed to central nervous system tumors, such as chiasmal optic gliomas, compromising hypothalamic and pituitary function. 2, 21 In a study comparing the clinical manifestations and natural history of optic pathway gliomas in children with NF1 compared with children without NF1, Listernick et al 22 reported CPP in 5 of 17 children with an optic glioma and NF1, in contrast to no cases of CPP in a group of children with an optic pathway glioma and no features of NF1. The latter group appears predisposed toward endocrinologic complications, because chiasmal involvement was significantly more common. This seems to suggest an association between CPP and NF1 itself, which cannot be attributed solely to the presence of a chiasma glioma. Our data support this association.
Possible causal mechanisms may be cerebral abnormalities still undetected at a neuroimaging level, such as slow-growing hamartomas. In 2 patients with CPP and 1 patient with GHD studied by T2-weighted MRI of the brain, high-signal-intensity foci were observed in the brainstem and supratentorial regions of the brain. These white matter lesions are common in children with NF1 and frequently increase in size or number, later resolving as the children get older. 23 They are, however, not likely to be correlated with the development of CPP or GHD, because they are classically localized outside the sellar and suprasellar regions of the brain. Another possible explanation could be abnormalities at a cellular level. The latter is supported by current evidence that suggests that neurofibromin, the protein encoded by the NF1 gene, is part of a signal transduction chain extending from extracellular signals to transcriptional regulation in the nucleus. 24 As a university clinic, we may examine more severe cases than generally seen in other hospitals. However, all but one case presented during followup. In contrast, the last child was referred with enlarged testes and pubic hair at 8 years of age. The high number of familial cases of NF1 observed in this ARTICLESgroup of children may be attributable to an ascertainment bias, although approximately half of the NF1 patients examined were familial cases and half were sporadic cases. The disease was inherited from both mothers and fathers.
In conclusion, CPP and GHD are important complications in children with NF1. Although a glioma of the optic chiasm is often encountered in these patients, CPP and GHD also appear to develop in the absence of an optic chiasm glioma. Diagnostic follow-up is essential in children with NF1, because premature manifestations of puberty and deviations from the growth curve may be recognized. Subsequently, early treatment with LHRH analogues or recombinant human GH, respectively, can be initiated with possible attainment of target height. Continuous monitoring will also help to establish any possible side effects of these interventions.
